Valvular & structural heart diseaseCohort study
Transjugular Transcatheter Tricuspid Valve Replacement
- Retrospective registry study
- multicentre
- 15 international centres
- compassionate use
Authors' conclusion
Transjugular TTVR appears to be a safe and effective treatment option for patients with severe TR with comparable outcomes in very large tricuspid anatomies.
Study context
- Population
- Patients with symptomatic tricuspid regurgitation (TR) undergoing transjugular transcatheter tricuspid valve replacement (TTVR) with the LuX-Valve Plus system, January 2022–February 202475.0% received devices ≥55 mm
- Participants
- 76 patients
- Exposure
- Transjugular TTVR; device size <55 vs ≥55 mm
- Outcome
- Procedural TR reduction, in-hospital death, adverse events and 1-month survival
Main finding
As reported in the abstract
Procedural TR reduction
TR reduced to ≤2+
94.7%
TR reduced to ≤1+
90.8%
Survival at 1 month
94.4%
Observational data: associations, not effects.
Further findings
TR at 1-month follow-up
- TR ≤2+
- 95.0%
- TR ≤1+
- 86.8%
NYHA functional class · 1 month
- NYHA functional class significantly improved
Safety
In-hospital adverse events · index hospitalisation
- In-hospital death
- 4 (5.3%)
- Cardiac surgery during index hospitalisation
- 4 (5.3%)
- Major in-hospital bleeding
- 5 (6.6%)
- New pacemaker implantation, overall cohort
- 3.9%
- New pacemaker implantation, pacemaker-naive
- 5.7%
- Valve thrombosis, stroke, MI or PE
- 0
Events within 30 days after TTVR
- Further pacemaker
- 1
- Further bleeding event
- 1
- Reintervention or surgery
- 2
Original publication
Transjugular Transcatheter Tricuspid Valve Replacement. JACC Cardiovasc Interv. Published 26 August 2024. doi:10.1016/j.jcin.2024.06.014
Summarised from the published abstract; every number is checked against it